Donald A. Bergstrom - Sep 8, 2022 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
President, R&D
Signature
/s/ Brian Adams, as attorney-in-fact
Stock symbol
RLAY
Transactions as of
Sep 8, 2022
Transactions value $
-$647,000
Form type
4
Date filed
9/8/2022, 08:22 PM
Previous filing
Sep 2, 2022
Next filing
Sep 29, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Options Exercise $103K +25K +27.88% $4.12 115K Sep 8, 2022 Direct F1, F2
transaction RLAY Common Stock Sale -$750K -25K -21.8% $30.00 89.7K Sep 8, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLAY Stock Option (Right to Buy) Options Exercise $0 -25K -18.59% $0.00 109K Sep 8, 2022 Common Stock 25K $4.12 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022.
F2 Includes 80,894 shares underlying restricted stock units.
F3 Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.